Struggling with belly fat despite diets? At DermaVue Thiruvalla, board-certified physicians
prescribe GLP-1 medications — Ozempic, Mounjaro, and Wegovy — specifically calibrated
for the Indian thin-fat phenotype. Physician-supervised. Dietitian-led. From ₹8,800/month.
✓ Ozempic from ₹8,800/mo✓ Mounjaro from ₹13,125/mo✓ Physician-Supervised✓ Dietitian-Led✓ Face-Saver Protocol
Long-term diet failure is not a willpower problem — it's biology. When you restrict calories,
your body fights back by increasing hunger hormones and slowing metabolism. GLP-1 medications
work at the hormonal root cause, not just the symptom. Combined with dietitian-led nutrition
and resistance training, the results are fundamentally different from anything you've tried before.
🧬
Targets hunger hormones
GLP-1 directly reduces hunger signals in the brain — constant hunger becomes manageable.
🔥
Burns visceral fat first
GLP-1 therapy preferentially reduces dangerous belly fat — not just subcutaneous fat.
💪
Preserves muscle mass
Combined with the SuperHuman protein protocol and resistance training, muscle is protected.
📊
Doctor-monitored safely
Regular body composition analysis, dose titration, and lab monitoring every step.
🍛
Adapted for Indian diet
Kerala-specific nutrition plans around rice, coconut, and local food patterns — not Western templates.
🌿
Sustainable long-term
Habit-building program designed so results last after medication tapering — not a quick fix.
Why Weight Loss Is Different for Indians — The Thin-Fat Reality
Research published in The Lancet reveals a troubling pattern specific to South Asian populations.
Indians with "normal" BMI often carry dangerous levels of hidden visceral fat that standard
Western weight charts completely miss.
⚠️ The Thin-Fat Phenotype — A Kerala-Specific Risk
Indians with BMI 22.3 show body fat percentages more than double their European
counterparts — 21.2% versus 9.1%. This means thousands of people in Thiruvalla and Pathanamthitta
district with "normal" weight carry dangerous metabolic risk that conventional medicine systematically misses.
DermaVue uses Indian-specific thresholds — not the Western BMI ≥25 standard:
BMI ≥23 + waist >90cm (men) or >80cm (women) = treatment-eligible. Central Kerala's
rice-heavy meals, coconut-based cuisine, and sedentary office jobs in Thiruvalla's business
corridor compound these genetic predispositions further.
⚠Waist >90cm (men) or >80cm (women)
⚠BMI >23 — not the Western standard of 25
⚠Family history of diabetes despite normal weight
⚠Insulin resistance without obvious obesity
⚠Acanthosis nigricans (dark neck or armpits)
⚠PCOS or pre-diabetic markers on blood tests
GLP-1 Medications Available at DermaVue Thiruvalla — With Pricing
Our physicians prescribe three evidence-based GLP-1 medications based on your individual
health profile, metabolic risk, and budget. All medications require a medical consultation and
prescription — they are not available over the counter or without physician supervision.
Ozempic
Semaglutide · Weekly Injection
₹8,800/month starting
Average weight loss~15%
DosingWeekly SC injection
MechanismGLP-1 agonist
Best forT2DM + weight loss
FDA approved✓ Yes
New in India
Wegovy
Semaglutide 2.4mg · Weekly Injection
₹10,850/month starting
Average weight loss~17%
DosingWeekly SC injection
MechanismHigh-dose GLP-1
Best forWeight management focus
Launched IndiaJune 2025
Most Effective
Mounjaro
Tirzepatide · Weekly Injection
₹13,125/month starting
Average weight loss~20–22%
DosingWeekly SC injection
MechanismDual GIP + GLP-1
vs Ozempic~47% more weight loss
Best forHigh insulin resistance
💡 Your physician selects the appropriate medication based on your health profile, metabolic markers, and budget.
Not everyone needs the most expensive option. Medication cost is in addition to the program fee.
All medications are prescription-only — doctor consultation required.
Glutathione & Metabolic Health at DermaVue
The DermaVue SuperHuman Program — Why Injections Alone Aren't Enough
Studies show 25–40% of weight lost during GLP-1 treatment can be muscle — not just fat.
Without proper protein intake and resistance training, patients risk slower metabolism,
easier weight regain, and "Ozempic face" (facial hollowing and aged appearance).
The SuperHuman Program was built to prevent exactly this.
1
Medical Evaluation (Physician)
Complete health history, body composition analysis (not just weight), lab panel (HbA1c, insulin, liver/kidney), risk assessment, medication prescription and dose titration.
2
Nutrition Coaching (Dietitian)
Weekly sessions with our lead dietitian at Thiruvalla. Protein targets (1.2–2.0g/kg), Kerala-adapted meal plans, carb management for insulin resistance, eating out strategies.
3
Resistance Training Protocol
Structured resistance exercise protocol to preserve skeletal muscle mass during rapid weight loss — the single most important factor preventing weight regain.
4
Dermatological Monitoring
DermaVue's unique advantage: skin quality assessment every 3 months. Face-Saver Protocol including oral collagen, retinol, and preventive aesthetic treatments to prevent Ozempic face.
DermaVue SuperHuman vs Typical Weight Loss Approach
Feature
DermaVue SuperHuman
Diet / Gym / Pills
Online GLP-1 Kits
Medical consultation
✓ Full physician review
✗ None
✗ No in-person
GLP-1 prescription
✓ Ozempic/Mounjaro/Wegovy
✗ Not available
Varies — often grey market
Dietitian support
✓ Weekly sessions
Sometimes
✗ Rarely
Indian-adapted protocol
✓ Kerala cuisine-specific
✗ Western templates
✗ Generic
Muscle preservation
✓ Resistance protocol + protein audit
Sometimes
✗ Not addressed
Skin monitoring (Ozempic face)
✓ Face-Saver Protocol
✗ Not available
✗ Not available
Body composition analysis
✓ InBody / quarterly
✗ Scale only
✗ Scale only
Dose titration
✓ Monthly physician review
N/A
Self-managed — risky
Long-term success rate
✓ High — habit-based
Low — 95% regain
Unknown — no follow-up
Check Your Eligibility for GLP-1 Weight Loss
Free physician consultation at DermaVue Thiruvalla. Opposite Indian Overseas Bank, Thukalassery.
Mon–Sat 9 AM–7 PM | Sun 10 AM–6 PM
Inside Kerala's Most Advanced Dermatology Clinic — DermaVue Tour
Who is Eligible for Medical Weight Loss at DermaVue Thiruvalla?
Full screening at consultation using our SuperHuman Eligibility Protocol.
✅ Eligible Candidates
•BMI ≥27 (obesity)
•BMI 23–27 with waist >90cm (M) or >80cm (F)
•Pre-diabetes or type 2 diabetes
•PCOS with metabolic involvement
•Hypertension with weight as contributing factor
•Fatty liver (NAFLD)
•Failed previous diet and exercise attempts
⚠️ Not Eligible (Contraindications)
•Personal/family history of medullary thyroid cancer
•MEN-2 syndrome
•Active or recent pancreatitis
•Pregnancy or breastfeeding / trying to conceive
•Severe kidney disease (eGFR <30)
•Active cancer
•History of severe eating disorder
Frequently Asked Questions — Medical Weight Loss Thiruvalla
GLP-1 medication costs at DermaVue Thiruvalla start from ₹8,800/month for Ozempic (semaglutide), ₹10,850/month for Wegovy (higher-dose semaglutide), and ₹13,125/month for Mounjaro (tirzepatide). Your physician recommends the appropriate medication based on your health profile, goals, and budget. Program fees are separate from medication costs.
Clinical trials show Mounjaro (tirzepatide) produces approximately 47% more weight loss than semaglutide-based medications (Ozempic/Wegovy) — about 20–22% total body weight loss vs 15%. However, the best choice depends on your individual health profile, insulin resistance level, budget, and tolerance. Our physicians assess and recommend the appropriate medication at consultation.
Yes. Wegovy (semaglutide 2.4mg) — the first medication specifically approved for weight management — is available at DermaVue Thiruvalla. Wegovy launched in India in June 2025. Starting price is ₹10,850/month. Your physician determines eligibility based on BMI and metabolic risk markers.
Research published in The Lancet shows Indians with BMI 22.3 carry body fat percentages more than double their European counterparts (21.2% vs 9.1%). This "thin-fat phenotype" means standard international BMI cutoffs underestimate metabolic risk in Indians. DermaVue uses Indian-specific thresholds: waist >90cm (men) or >80cm (women), BMI >23 as the treatment trigger — not the Western standard of BMI >25.
Studies show 25–40% of weight lost during GLP-1 treatment can be muscle, not just fat. The DermaVue SuperHuman Program specifically addresses this with adequate protein targets (1.2–2.0g per kg daily), resistance training protocol, regular body composition monitoring via InBody analysis, and nutritional coaching by our lead dietitian at Thiruvalla.
Eligible candidates: BMI ≥27 (or ≥23 with metabolic risk markers like pre-diabetes, PCOS, hypertension, or family history of diabetes), and no absolute contraindications. Absolute contraindications include personal/family history of medullary thyroid cancer, MEN-2 syndrome, active pancreatitis, pregnancy, and severe kidney disease (eGFR <30). Full screening at consultation.
The SuperHuman Program is DermaVue's physician-supervised, dietitian-led medical weight loss program. It combines GLP-1 medication prescribed by a physician, weekly dietitian coaching, a resistance training protocol to preserve muscle mass, and dermatological monitoring to prevent Ozempic face (facial hollowing). The program is headquartered at our Thiruvalla clinic serving Pathanamthitta district.
Most patients notice significantly reduced appetite within the first 1–2 weeks. Weight loss becomes noticeable by week 4–6. Meaningful results of 5–10% body weight loss occur by months 3–4. Maximum results of 15–22% total body weight loss are typically achieved at 12–18 months with sustained treatment and lifestyle adherence.
Without sustainable habit changes, research shows significant weight regain after stopping GLP-1 medications. This is why the DermaVue SuperHuman Program focuses on building lasting nutrition habits, improving metabolic health markers, and gradually tapering medications — not stopping abruptly. The program's goal is permanent metabolic improvement, not just temporary weight loss.
Absolutely essential. GLP-1 medications are prescription-only and require proper patient selection, dose titration, and monitoring. Unsupervised use risks inadequate treatment, missed contraindications, improper dose escalation, and poor management of side effects. Never use GLP-1 medications purchased online without physician supervision.
📍 Iykara Peniel Tower, Opposite Indian Overseas Bank, Thukalassery, Thiruvalla 689101🕘 Mon–Sat 9 AM–7 PM | Sun 10 AM–6 PMGet Directions →Call +91 80860 00608
Medical Disclaimer: This information is educational and does not constitute medical advice.
GLP-1 medications (Ozempic, Mounjaro, Wegovy) are prescription-only and require physician evaluation.
Individual results vary. All pricing is indicative and subject to change based on dose and market availability.
Always consult a qualified physician before starting any prescription medication.
Our Clinics
Visit Us at Any of Our 7 Clinics
Internationally certified dermatology care across Kerala and Tamil Nadu.
